CurrentAvMedPolicy Pub. 100-2

Intravenous Immune Globulin (IVIG) prior authorization for primary immunodeficiency

This form and policy govern prior authorization and step-edit requirements for outpatient IVIG products for treatment of primary immunodeficiency disorders for AvMed members; it affects prescribing providers requesting IVIG coverage.

Policy Summary

PayerAvMed

PolicyIntravenous Immune Globulin (IVIG) prior authorization for primary immunodeficiency

Policy CodePolicy Pub. 100-2

Change TypeNo material clinical or coverage changes

Effective Date

Next Review Date

Key ActionPrescribers must complete and sign the AvMed prior authorization/step-edit request form and fax it to AvMed with required clinical documentation.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

6 moInitial authorization duration

12 moReauthorization duration

3 moHigh maintenance reauth

500-1200 mg/dLTherapeutic IgG trough

<200 mg/dLInitial eligibility IgG

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Initial Therapy

Covered when ALL of the following are met for initial authorization

Primary diagnosis: Diagnosis is one of: severe combined immunodeficiency; X-linked or autosomal recessive agammaglobulinemia; common variable immunodeficiency; Wiskott-Aldrich syndrome; CD40 ligand deficiency (X-linked hyper-IgM syndrome); nuclear factor of κβ essential modifier deficiency; ataxia-telangiectasia; DiGeorge syndrome

IgG level: Member's IgG level is <200 mg/dL<200 mg/dL

submit documentation

Infection history: Member has history of multiple hard-to-treat infections as indicated by at least TWO of: 4+ ear infections in 1 year; 2+ serious sinus infections in 1 year; 2+ months antibiotics with little effect; 2+ pneumonias in 1 year; recurrent or deep skin abscesses; need for IV antibiotics to clear infections; 2+ deep-seated infections including septicemiaat least 2 conditions met

provider must submit number of hospital/ER visits and antibiotic courses in last 12 months

Antibody response: Member has a deficiency in producing antibodies in response to vaccination; titers drawn before challenge and between 4 and 8 weeks after vaccination

submit titer documentation

Switch from SQ to IV: If switching from subcutaneous (SQ) to IVIG, provider must indicate Yes or No on the prior authorization form

Product-specific step requirements: For Alyglo, Panzyga, Yimmugo: 90-day trial and failure of three preferred IVIG products. For Asceniv: 90-day trial and failure of ALL preferred IVIG products90-day trial

documentation of treatment failure must be submitted

Reauthorization

Reauthorization / Maintenance Therapy criteria

Duration and dosing: Reauthorization for maintenance: 12 months for titrated doses. High maintenance reauthorization: 3 months only. Doses above 1 g/kg approved based on recent ER/hospital visits plus IVIG <200 mg/kg within the last 3 months

Attempt to taper dose when improvement occurs (does not apply to primary immunodeficiency if Ig levels are maintained)

Clinical response: Member has experienced disease response as evidenced by at least ONE: decrease in frequency of infection or decrease in severity of infectionat least one response criterion

Admissions: Number of hospital/ER admissions for hard-to-treat infections has NOT increased from baseline since starting IVIG therapy

provide documentation of admissions; request may be denied without chart/lab support

Use of samples to initiate therapy does not meet step edit/preauthorization criteria. Providers should not rely on free or trial samples as evidence of prior therapy when submitting a prior authorization or step‑edit request for IVIG; previous therapies will be verified via pharmacy paid claims or submitted chart notes.

Coding and Dose Calculation

Preferred IVIG HCPCS/J-codesHCPCSCovered

J1556	Bivigam — Immune Globulin Intravenous (Human), 10% Liquid
J1561	Gammaked / Gamunex-C — Immune Globulin Injection (Human), 10% Caprylate/Chromatography Purified
J1572	Flebogamma DIF — Human Normal Immunoglobulin (IVIg)
J1557	Gammaplex — Immune Globulin Intravenous (Human) Liquid
J1569	Gammagard Liquid — Immune Globulin Infusion (Human), 10% Solution, for intravenous and subcutaneous administration
J1566	Gammagard S/D — Immune Globulin Intravenous (Human) Solvent/Detergent Treated (Freeze-Dried Concentrate)
J1568	Octagam — Immune Globulin Intravenous (Human) liquid preparation
J1459	Privigen — Immune Globulin Intravenous (Human), 10% Liquid

Non-preferred IVIG HCPCS/J-codesHCPCSCovered

JI552	Alyglo — Immune Globulin Intravenous, Human-stwk
J1554	Asceniv — Immune Globulin Intravenous (Human) - slra 10% Liquid
J1576	Panzyga — Immune Globulin Intravenous (Human) - ifas 10% Liquid Preparation
J1553	Yimmugo — Immune globulin intravenous, human, 10% liquid

inv-06: Adjusted body weight calculation / IBW

Adjusted body weight formulaAdjusted body weight = IBW + 0.5 (actual body weight - IBW)

IBW formula — malesIBW (kg) for males = 50 + 2.3 × (height in inches - 60)

IBW formula — femalesIBW (kg) for females = 45.5 + 2.3 × (height in inches - 60)

What Providers Must Do

Prior Authorization

Prior Authorization Required — Complete & Legible Form

The prescribing physician must sign and clearly print their name (preprinted stamps not valid) on the AvMed prior authorization/step-edit request form and fax it to 1-877-535-1391. All required fields on the form must be completed legibly. If information provided is incomplete, incorrect, or illegible, authorization can be delayed or denied.

Prescriber signature and printed name required (stamps not valid).
Fax completed form to 1-877-535-1391.
Include complete member and provider contact information (member name, AvMed #, DOB, office contact, phone, fax, NPI).
Provide full drug information (form/strength, dosing schedule, length of therapy, diagnosis, ICD code, height, weight).
Dosing should use adjusted body weight if actual body weight is ≥20% above IBW; if adjusted BW is not accepted, only partial approval may be granted.

Step Therapy

Step Therapy Requirement for Non-Preferred IVIG Products

Requests for certain non-preferred IVIG products require documented trials and failures of preferred products before approval will be considered. Documentation of treatment failure must be submitted with the request and all clinical documentation (labs, diagnostics, chart notes) must be provided or the request may be denied.

For Alyglo, Panzyga, and Yimmugo requests: member must have a 90-day trial and failure of three (3) preferred IVIG products; submit documentation of treatment failure.
For Asceniv requests: member must have a 90-day trial and failure of ALL preferred IVIG products; submit documentation of treatment failure.
Include supporting data such as number of hospital/ER visits for hard-to-treat infections in the last 12 months and number of antibiotics prescribed for such infections in the last 12 months.

Documentation Required

Documentation Required — Labs, Visits, and Clinical History

Providers must submit supporting clinical documentation to demonstrate medical necessity. Missing documentation or incomplete requests can lead to delays or denials of authorization.

Submit member's IgG level (e.g., <200 mg/dL for initial approval) and relevant recent IgG trough levels for reauthorization.
Provide evidence of multiple hard-to-treat infections (at least two qualifying criteria such as ≥4 ear infections in 1 year, ≥2 serious sinus infections in 1 year, ≥2 pneumonias in 1 year, recurrent deep skin abscesses, need for IV antibiotics, or ≥2 deep-seated infections).
Provide vaccination titer documentation: titers drawn before vaccine challenge and between 4–8 weeks after vaccination.
For reauthorization, provide documentation of disease response (e.g., decreased frequency or severity of infections), and that hospital/ER admissions have not increased from baseline since starting IVIG.
For doses above 1 g/kg, approval may require recent ER/hospital visit documentation plus IVIG <200 mg/kg within the last 3 months.

Clinical Background

Primary immunodeficiency disorders frequently require immunoglobulin replacement therapy (IVIG) when patients have low IgG levels and recurrent, serious infections. IVIG dosing should be calculated using adjusted body weight when actual body weight is ≥20% above ideal body weight; the policy defines adjusted body weight as IBW + 0.5 × (actual − IBW) with standard IBW formulas for males and females.

Trough IgG monitoring and vaccine/titer challenge testing are used to assess antibody production and to guide therapy. For initial authorization the form specifies an initial authorization duration of 6 months and requires documentation of diagnosis, IgG level, infection history, and antibody response testing as part of the clinical rationale for IVIG.

OpenPayer

Intravenous Immune Globulin (IVIG) prior authorization for primary immunodeficiency

Coverage Criteria for IVIG (Primary Immunodeficiency)

Coding and Dose Calculation

What Providers Must Do

Clinical Background

Definitions and Calculations